CryoLife Aims To Grab Share From Big Artificial Valve Players With On-X Buy
This article was originally published in Clinica
Executive Summary
CryoLife is expanding its cardiac surgery portfolio, which has traditionally focused on tissue-based implants, to include artificial heart valves, after agreeing to acquire On-X Life Technologies in a $130m cash-and-stock deal.